{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-001572","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.636348+00:00","generated_at":"2026-06-19T07:11:34.346507+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harmony Biosciences Q4 2022 net revenue $128.3M (+41% YoY); full-year net income $181.5M","bullets":["Q4 net product revenue $128.3M, up 41% YoY; average patients on WAKIX ~4,900.","GAAP net income Q4 $48.5M ($0.79 diluted EPS); non-GAAP adjusted $61.9M ($1.01).","Full year 2022 net revenue $437.9M (+43% YoY); net income $181.5M.","Phase 3 idiopathic hypersomnia INTUNE study continues with strong momentum."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-001572","json":"https://secwatch.observer/filing/0001558370-23-001572.json","markdown":"https://secwatch.observer/filing/0001558370-23-001572.md","text":"https://secwatch.observer/filing/0001558370-23-001572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023001572/0001558370-23-001572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023001572/hrmy-20230221x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:11:34.346507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f9c52a77aced6fc218b0956dd5c71c2837f1ce52","claim":"Harmony Biosciences Holdings, Inc. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On February 21, 2023, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023001572/0001558370-23-001572-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}